Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 57

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 57
---
 with a weighted average exercise price of $7.00, no intrinsic value and a weighted average remaining life of 95 months.

The fair value of options granted during the nine months ended June 30, 2025 and 2024 was estimated using the Black-Scholes option valuation model using the following assumptions:

			Nine Months Ended June 30, 2024

			Risk free interest rate

			4.92
			%

			Expected life

			5 years

			Expected share price volatility

			97.26
			%

			Expected dividend yield

			0.00
			%

As of June 30, 2025, the Company had approximately $0.01 million of unrecognized share-based compensation expense, which is expected to be recognized over a period of 15 months.

Restricted share units (RSU)

The Company’s 2019 Plan allows restricted share units (RSUs) to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the RSU term is not to exceed 10 years. The fair value is based on the 5-day VWAP of the Company’s Common Shares up to the date of grant.

14

The following is a summary of changes in the status of RSUs from October 1, 2024 through June 30, 2025:

			Number of RSU (#)

			Weighted Average Grant Date Fair Value

			Nine Months Ended June 30, 2025

			Balance - September 30, 2024

			63,204

			$
			5.10

			Granted

			1,207,856

			2.00

			Exercised

			(2,486
			)

			5.60

			Balance - June 30, 2025

			1,268,574

			$
			2.15

			Nine Months Ended June 30, 2024

			Balance - September 30, 2023

			33,045

			$
			5.60

			Granted

			19,772

			4.52

			Balance - June 30, 2024

			52,817

			$
			5.20

The following table summarizes information about the RSUs under the 2019